Search Results - Sai‐Hong Ignatius Ou

Refine Results
  1. 1
    Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond

    Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond by Sai‐Hong Ignatius Ou

    Published 2011
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer

    Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer by Sai‐Hong Ignatius Ou, Jason A. Zell

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry

    Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-small Cell Lung Cancer Descriptors Using Data from 23,583 Patients in the California Cancer Registry by Sai‐Hong Ignatius Ou, Jason A. Zell

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies

    Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies by Sai‐Hong Ignatius Ou, Jason A. Zell

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition

    The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition by Sai‐Hong Ignatius Ou, Jason A. Zell

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020

    Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020 by Sai‐Hong Ignatius Ou, Viola W. Zhu

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

    Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno by Danielle Brazel, Sai‐Hong Ignatius Ou, Misako Nagasaka

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Taletrectinib for the treatment of <i>ROS-1</i> positive non-small cell lung cancer: a drug evaluation of phase I and II data

    Taletrectinib for the treatment of <i>ROS-1</i> positive non-small cell lung cancer: a drug evaluation of phase I and II data by Misako Nagasaka, Danielle Brazel, Sai‐Hong Ignatius Ou

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status

    Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status by Sai‐Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity

    Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity by Sai‐Hong Ignatius Ou, Argyrios Ziogas, Jason A. Zell

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Liquid Biopsy to Identify Actionable Genomic Alterations

    Liquid Biopsy to Identify Actionable Genomic Alterations by Sai‐Hong Ignatius Ou, Misako Nagasaka, Viola W. Zhu

    Published 2018
    Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020

    Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020 by Sai‐Hong Ignatius Ou, Viola W. Zhu, Misako Nagasaka

    Published 2020
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC

    From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC by Sai‐Hong Ignatius Ou, Alexandria TM Lee, Misako Nagasaka

    Published 2023
    Get full text
    Revisão
    Save to List
    Saved in:
  14. 14
    Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC

    Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC by Zhaohui Arter, Kevin Shieh, Misako Nagasaka, Sai‐Hong Ignatius Ou

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

    Targeting MET in Lung Cancer: Will Expectations Finally Be MET? by Alexander Drilon, Federico Cappuzzo, Sai‐Hong Ignatius Ou, D. Ross Camidge

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable

    The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable by Thanyanan Reungwetwattana, Ying Liang, Viola W. Zhu, Sai‐Hong Ignatius Ou

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  17. 17
    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC

    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC by Shannon Zhang, Misako Nagasaka, Viola W. Zhu, Sai‐Hong Ignatius Ou

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer

    Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer by Leow Pay Chin, Ross A. Soo, Richie Soong, Sai‐Hong Ignatius Ou

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  19. 19
    Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib

    Asymptomatic Profound Sinus Bradycardia (Heart Rate ≤45) in Non-small Cell Lung Cancer Patients Treated with Crizotinib by Sai‐Hong Ignatius Ou, Michele C. Azada, Joni Dy, Jonathan A. Stiber

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Alectinib Induces a Durable (&amp;gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis

    Alectinib Induces a Durable (&amp;gt;15 Months) Complete Response in an <i>ALK</i>-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomening... by Sai‐Hong Ignatius Ou, Karen R. Sommers, Michele C. Azada, Edward B. Garon

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: